Targeting cancer-related inflammation in the era of immunotherapy

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor

(2016) Shin Foong Ngiow et al.   CANCER RESEARCH

Germline NLRP1 Mutations Cause Skin Inflammatory and Cancer Susceptibility Syndromes via Inflammasome Activation

(2016) Franklin L. Zhong et al.   CELL

Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies

(2016) Camille Guillerey et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

(2016) Christina Pfirschke et al.   IMMUNITY

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer

(2016) Cora Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

The ever-expanding role of HIF in tumour and stromal biology

(2016) Edward L. LaGory et al.   NATURE CELL BIOLOGY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Macrophage PI3K  Drives Pancreatic Ductal Adenocarcinoma Progression

(2016) M. M. Kaneda et al.   Cancer Discovery

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer

(2015) E. M. Dijkgraaf et al.   ANNALS OF ONCOLOGY

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms

(2015) M. Cioffi et al.   CLINICAL CANCER RESEARCH

HIF-1 at the crossroads of hypoxia, inflammation, and cancer

(2015) Kuppusamy Balamurugan   INTERNATIONAL JOURNAL OF CANCER

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

(2015) Stefano Ugel et al.   JOURNAL OF CLINICAL INVESTIGATION

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Inflammasomes: mechanism of action, role in disease and therapeutics

(2015) Haitao Guo et al.   NATURE MEDICINE

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

(2015) David Hong et al.   Science Translational Medicine

Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages

(2015) Aya Kakizaki et al.   OncoImmunology

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

(2014) J. San-Miguel et al.   BLOOD

Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors

(2014) Laura Tornatore et al.   CANCER CELL

Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma

(2014) D. T. Weed et al.   CLINICAL CANCER RESEARCH

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

(2014) E. Angevin et al.   CLINICAL CANCER RESEARCH

IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis

(2014) Matjaz Rokavec et al.   JOURNAL OF CLINICAL INVESTIGATION

Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells

(2014) P. Sinha et al.   JOURNAL OF IMMUNOLOGY

Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer

(2014) Kimmie Ng et al.   JNCI-Journal of the National Cancer Institute

Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma

(2014) Tobias Bald et al.   NATURE

Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

(2014) T. Bald et al.   Cancer Discovery

Targeting Cancer-Derived Adenosine:New Therapeutic Approaches

(2014) A. Young et al.   Cancer Discovery

The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target

(2013) A. Neil Barclay et al.   Annual Review of Immunology

A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis

(2013) J. Mascarenhas et al.   BLOOD

Mechanisms of action of tasquinimod on the tumour microenvironment

(2013) E. Raymond et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

(2013) Woondong Jeong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma

(2013) Xi Wu et al.   CANCER LETTERS

Agonistic CD40 Antibodies and Cancer Therapy

(2013) R. H. Vonderheide et al.   CLINICAL CANCER RESEARCH

Tumor Necrosis Factor-α Blocks Differentiation and Enhances Suppressive Activity of Immature Myeloid Cells during Chronic Inflammation

(2013) Moshe Sade-Feldman et al.   IMMUNITY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cancer risk in immune-mediated inflammatory diseases (IMID)

(2013) Rudi Beyaert et al.   Molecular Cancer

Disrupting Cytokine Signaling in Pancreatic Cancer

(2013) Christina Wu et al.   PANCREAS

Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue

(2012) Stephen D. Hursting et al.   Annals of the New York Academy of Sciences

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia

(2012) Yuliya Pylayeva-Gupta et al.   CANCER CELL

Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State

(2012) Michele W. L. Teng et al.   CANCER RESEARCH

NF-κB and the link between inflammation and cancer

(2012) Joseph A. DiDonato et al.   IMMUNOLOGICAL REVIEWS

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

(2012) Kenneth J. Pienta et al.   INVESTIGATIONAL NEW DRUGS

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis

(2012) Catherine de Martel et al.   LANCET ONCOLOGY

Natural Innate and Adaptive Immunity to Cancer

(2011) Matthew D. Vesely et al.   Annual Review of Immunology

Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression

(2011) Michael C. Schmid et al.   CANCER CELL

Tumor Promotion via Injury- and Death-Induced Inflammation

(2011) Ali Kuraishy et al.   IMMUNITY

IFN-  Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity

(2011) S. Terawaki et al.   JOURNAL OF IMMUNOLOGY

Regulation of Immune Responses by Prostaglandin E2

(2011) P. Kalinski   JOURNAL OF IMMUNOLOGY

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

(2011) David G. DeNardo et al.   Cancer Discovery

HMGB1 and RAGE in Inflammation and Cancer

(2010) Gary P. Sims et al.   Annual Review of Immunology

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma

(2010) J M G Larkin et al.   BRITISH JOURNAL OF CANCER

TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion

(2010) Y Wu et al.   BRITISH JOURNAL OF CANCER

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

(2010) T. B. Dorff et al.   CLINICAL CANCER RESEARCH

Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability

(2009) F. Colotta et al.   CARCINOGENESIS

The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment

(2009) A. Greenhough et al.   CARCINOGENESIS

Development of HIF-1 inhibitors for cancer therapy

(2009) Barbara Onnis et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component

(2009) John A. Lust et al.   MAYO CLINIC PROCEEDINGS

Treatment of rheumatoid arthritis: state of the art 2009

(2009) Ronald F. van Vollenhoven   Nature Reviews Rheumatology

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

(2008) Pingyan Cheng et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE

The S100A8–serum amyloid A3–TLR4 paracrine cascade establishes a pre-metastatic phase

(2008) Sachie Hiratsuka et al.   NATURE CELL BIOLOGY

Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase

(2008) Patrizia Pellegatti et al.   PLoS One